Table 1.
Characterization of NLCs (mean±SD, n=3)
| NLCs | Particle size (nm) | PDI | Zeta potential (mV) | RVC EE (%) | DMDT EE (%) | RVC DL (%) | DMDT DL (%) |
|---|---|---|---|---|---|---|---|
| HA-TPGS-RVC/DMDT-NLCs | 108.2±3.3 | 0.16±0.03 | −30.7±2.8 | 89.5±2.9 | 88.1±2.1 | 15.9±0.8 | 3.6±0.6 |
| HA-TPGS-RVC-NLCs | 106.5±3.7 | 0.17±0.02 | −28.9±3.2 | 87.6±3.1 | / | 16.1±0.9 | / |
| HA-TPGS-DMDT-NLCs | 105.7±3.9 | 0.18±0.03 | −31.3±2.9 | / | 85.3±3.2 | / | 3.3±0.5 |
| TPGS-RVC/DMDT-NLCs | 86.3±2.9 | 0.15±0.02 | −21.2±2.5 | 90.4±2.7 | 86.5±2.9 | 17.3±0.9 | 3.2±0.6 |
| RVC/DMDT-NLCs | 64.5±3.1 | 0.16±0.02 | −15.6±2.3 | 91.2±2.5 | 89.7±2.6 | 17.1±0.7 | 3.8±0.5 |
| HA-TPGS-NLCs | 105.1±2.8 | 0.14±0.01 | −29.9±2.5 | / | / | / | / |
Abbreviations: HA, hyaluronic acid; TPGS, tocopheryl polyethylene glycol 1000 succinate; RVC, ropivacaine; DMDT, dexmedetomidine; NLCs, nanostructured lipid carriers; PDI, polydispersity index; EE, encapsulation efficiency; DL, drug loading.